Abeona Therapeutics Inc

ABEO USD0.01
Create an alert
Sell
$2.39
Buy
$2.47
$0.03 (1.22%)
Last updated today at
Back to dashboard

Company Information

About this company

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases. The Company's portfolio includes ZEVASKYN (prademagene zamikeracel), the autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB); ABO-801, a Phase III-ready product candidate for eosinophilic esophagitis (EoE); and ABO-701 (PSMA-SIR-T), an investigational engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA). ZEVASKYN is a type of gene therapy made from a patient's own skin cells that is surgically applied to treat wounds in both children and adults who have RDEB. The Company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. ABO-801 is a once-daily oral disintegrating tablet formulation of fluticasone propionate.

Key people

Vishwas Seshadri
President, Chief Executive Officer, Director
Joseph W. Vazzano
Chief Financial Officer
Brendan O'Malley
Chief Legal Officer
Madhav Vasanthavada
Chief Commercial Officer
Leila Alland
Independent Director
Mark J. Alvino
Independent Director
Faith L. Charles
Independent Director
Eric Crombez
Independent Director
Keith A. Goldan
Independent Director
Click to see more

Key facts

  • Shares in issue
    57.15m
  • EPIC
    ABEO
  • ISIN
    US00289Y2063
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $156.01m
  • Employees
    226
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.